Solventum Corporation (NYSE:SOLV) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Solventum Corporation (NYSE:SOLV) have received an average recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $84.25.

Several equities analysts have recently issued reports on SOLV shares. Rothschild & Co Redburn started coverage on shares of Solventum in a research note on Tuesday, March 24th. They set a “sell” rating and a $60.00 price target for the company. Wall Street Zen downgraded shares of Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Piper Sandler dropped their price target on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Stifel Nicolaus dropped their price target on shares of Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Finally, Wells Fargo & Company dropped their price target on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 6th.

Insider Buying and Selling at Solventum

In other news, Director Amy Mcbride Wendell acquired 1,475 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was bought at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the transaction, the director directly owned 5,039 shares in the company, valued at $342,803.17. This represents a 41.39% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.24% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Solventum

Large investors have recently modified their holdings of the company. Assetmark Inc. lifted its position in shares of Solventum by 21.4% during the fourth quarter. Assetmark Inc. now owns 725 shares of the company’s stock valued at $57,000 after purchasing an additional 128 shares in the last quarter. Allworth Financial LP lifted its position in shares of Solventum by 2.8% during the third quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock valued at $350,000 after purchasing an additional 129 shares in the last quarter. Hilltop National Bank lifted its position in shares of Solventum by 71.3% during the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after purchasing an additional 129 shares in the last quarter. CIBC Private Wealth Group LLC lifted its position in shares of Solventum by 0.5% during the third quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock valued at $1,804,000 after purchasing an additional 134 shares in the last quarter. Finally, BOKF NA lifted its position in shares of Solventum by 6.9% during the third quarter. BOKF NA now owns 2,193 shares of the company’s stock valued at $160,000 after purchasing an additional 141 shares in the last quarter.

Solventum Price Performance

Shares of NYSE:SOLV opened at $75.13 on Monday. The company has a market cap of $13.01 billion, a price-to-earnings ratio of 9.21, a PEG ratio of 1.17 and a beta of 0.59. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The firm has a 50 day simple moving average of $69.57 and a 200 day simple moving average of $75.04. Solventum has a one year low of $62.38 and a one year high of $88.20.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.35 by $0.13. The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm’s revenue was down 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Research analysts predict that Solventum will post 6.58 earnings per share for the current fiscal year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.